Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer.
Dittrich C, Coudert B, Paz-Ares L, Caponigro F, Salzberg M, Gamucci T, Paoletti X, Hermans C, Lacombe D, Fumoleau P; European Organization for Research and Treatment of Cancer--Early Clinical Studies Group/New Drug Development Programme (EORTC-ECSG/NDDP). Dittrich C, et al. Among authors: fumoleau p. Eur J Cancer. 2003 Feb;39(3):330-4. doi: 10.1016/s0959-8049(02)00559-2. Eur J Cancer. 2003. PMID: 12565985 Clinical Trial.
UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial.
Ravaud A, Borner M, Schellens JH, Geoffrois L, Schöffski BP, Kroon K, Wanders J, Hanauske AR, Fumoleau P; EORTC-ECSG. Ravaud A, et al. Among authors: fumoleau p. Eur J Cancer. 2001 Sep;37(13):1642-7. doi: 10.1016/s0959-8049(01)00187-3. Eur J Cancer. 2001. PMID: 11527690 Clinical Trial.
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P. Borner MM, et al. Among authors: fumoleau p. Eur J Cancer. 2002 Feb;38(3):349-58. doi: 10.1016/s0959-8049(01)00371-9. Eur J Cancer. 2002. PMID: 11818199 Clinical Trial.
Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours.
Awada A, Eskens FA, Piccart M, Cutler DL, van der Gaast A, Bleiberg H, Wanders J, Faber MN, Statkevich P, Fumoleau P, Verweij J; EORTC Early Clinical Studies Group. Awada A, et al. Among authors: fumoleau p. Eur J Cancer. 2002 Nov;38(17):2272-8. doi: 10.1016/s0959-8049(02)00379-9. Eur J Cancer. 2002. PMID: 12441264 Clinical Trial.
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).
Chollet P, Schöffski P, Weigang-Köhler K, Schellens JH, Cure H, Pavlidis N, Grünwald V, De Boer R, Wanders J, Fumoleau P; EORTC Early Clinical Studies Group. Chollet P, et al. Among authors: fumoleau p. Eur J Cancer. 2003 Jun;39(9):1264-70. doi: 10.1016/s0959-8049(03)00237-5. Eur J Cancer. 2003. PMID: 12763215 Clinical Trial.
280 results